PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8962472

A codiffusing system as a novel model for capillary wall charge selectivity.

M F Smit·W D Comper
View original source ↗Export metadata ↓

Abstract

The electrostatic interaction associated with polyion-polyion interaction has been thought to be the basis for the differential transport of charged transport probes across the capillary wall. The charge of the transport probe may interact with the negative charges of capillary wall cell surfaces and the intercellular glycocalyx or extracellular matrix. This study has set out to quantitate the exact nature of the polyion-polyion interaction through the theoretical and experimental study of the partition-diffusion of albumin in solutions of anionic polysaccharides (dextran sulfate or heparin) at concentrations up to 250 meq 1(-1) or at an average intercharge distance of 2.2 nm, as compared with solutions of uncharged dextran at the same volume concentration. The results demonstrate that the albumin partition-diffusion is exactly the same in dextran sulfate, heparin and uncharged dextran matrices of the same polymer volume fraction. These results confirm previous studies from this laboratory that the charge effect through polyion-polyion interaction under physiological conditions is negligible.

Explore related subjects

AlbuminsCapillariesComputer SimulationDextransDiffusionExtracellular SpaceModels, BiologicalPolysaccharidesSolutionsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M F Smit, W D Comper. 1996-11-29. A codiffusing system as a novel model for capillary wall charge selectivity.. https://doi.org/10.1016/s0301-4622(96)02214-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Human albumin administration in critically ill patients: systematic review of randomised controlled trials.

OBJECTIVE: To quantify effect on mortality of administering human albumin or plasma protein fraction during management of critically ill patients. DESIGN: Systematic review of randomised controlled trials comparing administration of albumin or plasma protein fraction with no administration or with administration of crystalloid solution in critically ill patients with hypovolaemia, burns, or hypoalbuminaemia. SUBJECTS: 30 randomised controlled trials including 1419 randomised patients. MAIN OUTCOME MEASURE: Mortality from all causes at end of follow up for each trial. RESULTS: For each patient category the risk of death in the albumin treated group was higher than in the comparison group. For hypovolaemia the relative risk of death after albumin administration was 1.46 (95% confidence interval 0.97 to 2.22), for burns the relative risk was 2.40 (1.11 to 5.19), and for hypoalbuminaemia it was 1.69 (1.07 to 2.67). Pooled relative risk of death with albumin administration was 1.68 (1.26 to 2.23). Pooled difference in the risk of death with albumin was 6% (95% confidence interval 3% to 9%) with a fixed effects model. These data suggest that for every 17 critically ill patients treated with albumin there is one additional death. CONCLUSIONS: There is no evidence that albumin administration reduces mortality in critically ill patients with hypovolaemia, burns, or hypoalbuminaemia and a strong suggestion that it may increase mortality. These data suggest that use of human albumin in critically ill patients should be urgently reviewed and that it should not be used outside the context of rigorously conducted, randomised controlled trials.

Albumins↗